Laverock secures funding for gene-control platform development
pharmafile | June 4, 2026 | News story | Research and Development | Laverock Therapeutics
Laverock Therapeutics has been awarded more than £2.2m in grant funding to support development of its gene-control platform and expand research into therapeutic areas beyond oncology.
The biotechnology company said the funding will support further development of its single-cell and artificial intelligence (AI)-powered technology, which is designed to create disease-responsive advanced therapies.
One project will focus on applying the platform to T-cell therapies for solid tumours. Using patient datasets and AI-driven analysis, the company aims to identify combinations of therapeutic features that could improve efficacy and safety in cancer treatment.
A second grant-funded programme will support expansion of the company’s macrophage-based therapies into non-oncology indications. The work will be undertaken as part of a wider consortium involving disease-area and product-development specialists.
Laverock said its technology has already been evaluated across several cell types and therapeutic applications, including engineered T-cells and macrophages for cancer as well as hypoimmunogenic pancreatic islet cell approaches for type 1 diabetes.
The new awards build on previous non-dilutive funding secured through UK Research and Innovation programmes.
David Venables, Chief Executive Officer of Laverock Therapeutics, said the grants would support both platform development and progression of the company’s therapeutic pipeline.
He commented: “Success in these two highly competitive grant competitions provides further validation of our approach and will enable us to expand our efforts across platform and product development.
“As we push towards the clinic for our lead programme this additional funding will help unlock the true breadth of what our technology can achieve.”
Advanced cell and gene therapies are attracting increasing interest across a range of diseases, with researchers exploring ways to improve treatment precision, safety and long-term effectiveness.
